How Pfizer Profited From the Pandemic

Analysis by Dr. Joseph Mercola  Fact Checked July 18, 2022

The COVID-19 pandemic has been a real boon to Pfizer. Not only has it doubled Pfizer’s
annual revenue, it has also given the drugmaker unique weight in determining U.S. health
policy — something that concerns even staunch vaccine-pushers like Dr. Paul Offit

Pfizer’s revenue in 2021 was $81.3 billion — approximately double that of 2020 — and the
COVID shot accounted for $36.78 billion of that

Pfizer’s COVID jab dominates 70% of the U.S. and European markets, and Paxlovid, its
COVID drug, has become a standard treatment choice in hospitals. This despite findings
showing the shot doesn’t prevent infection or transmission, and that Paxlovid causes
severe rebound and supercharges mutations

The U.S. had thrown away 82.2 million expired COVID jab doses as of mid-May 2022, yet
the Biden administration ordered another 105 million doses at the end of June 2022 for a
fall booster campaign that will cost taxpayers $3.2 billion

Pfizer’s contracts are almost exclusively slanted in Pfizer’s favor. They’re guaranteed
payment while having no financial liability for injuries and deaths, and it appears this
indemnification applies even if they were to be found guilty of fraud

You may also like these